头孢他啶及头孢曲松治疗儿童支气管肺炎的成本-效果分析

目的评价头孢他啶(复达欣)和头孢曲松(罗氏芬)治疗儿童支气管肺炎的临床疗效及经济效果。方法采用回顾性研究方法,将2011年1月—2012年12月确诊的184例支气管肺炎患儿按治疗方案分为2组,即头孢他啶(A)组和头孢曲松(B)组,运用成本-效果分析方法进行评价。结果头孢他啶和头孢曲松治疗支气管肺炎总有效率分别为91.01%和95.79%,效果差异无统计学意义(P>0.05);两组成本-效果比为10.06(头孢他啶组)和5.54(头孢曲松组);药品费用下降15%,两组的成本-效果比仍具一致性。结论头孢曲松组治疗儿童支气管肺炎比头孢他啶组更经济,更符合药物经济学原则。

Cost-efectiveness Analysis of Ceftazidime and Ceftriaxone sodium for Treatment of Bronchopneumonia in Children

Objective To evaluate the cost-effectiveness of ceftazidime and ceftriaxone sodium on the treatment of bronchopneumonia in children. Methods 184 cases with bronchopneumonia in children were divided into ceftazidime group （A group）and ceftriaxone sodium group （B group）according to the treatment plan from Jan.2011 to Dec.2012.The clinical efficacy and cost of medicines were analyzed. Results The efficiency of A was 91.01% and 95.79% in the B. The difference was not statistically significant between groups （P 〉 0.05） ; The cost-effectiveness ratio of A group and B group were respectively 10.06 and 5.54.When drug prices down 15%, there was still consistent with the two groups in cost-effectiveness. Conclusion Ceftriaxone sodium group was more economical than ceftazidime group in the treatment of bronchopneumonia in children.